The assessment of human regional drug absorption of free acid and sodium salt forms of acipimox, in healthy volunteers, to direct modified release formulation strategy

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 9, 2009, Pages 508-516

  Menona, Rajeev ^a   Cefalib, Eugenio ^b   Wildingc, Ian ^c   Wrayc, Heather ^c   Connorc, Alyson ^c  

^a ABBOTT LABORATORIES   (United States)

^b Cortia Corporation ^*  (United States)

^c Quotient Clinical   (United Kingdom)

Author keywords

Acipimox; Enterion capsule; Type II diabetes

Indexed keywords

ACID; ACIPIMOX; SODIUM;

ADULT; ARTICLE; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; DRUG INFORMATION; DRUG STRUCTURE; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE MUCOSA PERMEABILITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; SMALL INTESTINE; VOLUNTEER;

ADULT; ANTILIPEMIC AGENTS; BIOLOGICAL AVAILABILITY; COLON; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INTESTINE, SMALL; MALE; MIDDLE AGED; PERMEABILITY; PYRAZINES; SALTS; SOLUBILITY; YOUNG ADULT;

EID: 73349109849     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.683     Document Type: Article

References (14)

1. Olbetam Capsules 250. Summary of Product Characteristics. Pharmacia Ltd: Sandwich, Kent, 2007.
2. Musatti L, Maggi E, Moro E, Valzelli G, Tamassi V. Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent. J Int Med Res 1981; 9: 381-386.
3. Efthymiopoulos C, Strolin Benedetti M, Poggesi I, Ruff F, Basileo G, Musatti L. Pharmacokinetics of acipimox and of its N-deoxy metabolite following single and repeated oral administration to healthy volunteers. Therapie 1993; 48: 23-26.
4. Note for Guidance on Quality of Modified Release Products. European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Committee For Proprietary Medicinal Products (CPMP), London, 29 July 1999. CPMP/QWP/604/96.
5. Hardy JG, Wilson CG, Wood E. Drug delivery to the proximal colon. J Pharm Pharmacol 1985; 37: 874-877.
6. Hardy JG, Healy JNC, Lee SW, Reynolds JR. Gastrointestinal transit of an enteric coated delayed release 5-aminosalicylic acid tablet. Aliment Pharmacol Ther 1987; 1: 209-216.
7. Wilding I, Hirst P, Connor A. Development of a new engineering-based capsule for human drug absorption studies. PSTT 2000; 3: 385-392.
8. Oo C, Snell P, Barrett J, Dorr A, Liu B, Wilding IR. Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. Int J Pharm 2003; 257: 297-299.
9. Martin NE, Collison KR, Martin LL, et al. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers. J Clin Pharmacol 2003; 43: 529-538.
10. Kelly KA. Gastric emptying of liquids and solids: roles of proximal and distal stomach. Am J Physiol 1980; 230: G71-G76.
11. Coupe AJ, Davis SS, Evans DF, Wilding IR. Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility. Pharm Res 1991; 8: 1281-1285.
12. Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1991; 8: 360-364.
13. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27: 886-892.
14. Marvola M, Aito H, Pohto P, Kannikoski A, Nykanen S, Kokkonen P. Gastrointestinal transit and concomitant absorption of verapamil from a single-unit sustained-release tablet. Drug Dev Ind Pharm 1987; 13: 1593-1609.